Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy.

British journal of cancer - 3 Mar 2015

Teft W A, Welch S, Lenehan J, Parfitt J, Choi Y-H, Winquist E, Kim R B

Abstract excerpt

BACKGROUND: Treatment of advanced and metastatic colorectal cancer with irinotecan is hampered by severe toxicities. The active metabolite of irinotecan, SN-38, is a known substrate of drug-metabolising enzymes, including UGT1A1, as well as OATP and ABC drug transporters. METHODS: Blood samples (...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Phytogenic
Share to Camptothecin
Share to Irinotecan

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Liver-Specific Organic Anion Transporter 1

Share to Multidrug Resistance-Associated Protein 2

Share to Organic Anion Transporters

Share to Organic Anion Transporters, Sodium-Independent

Share to Solute Carrier Organic Anion Transporter Family Member 1B3

Source

Open in PubMed Open full text

Identifiers

PMID: 25611302
DOI: 10.1038/bjc.2015.5
PMCID: PMC4453959

Genes

ABCC2
ABCC5
APC
CES1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-25611302-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy.PMID 25611302Read ↗

Pharmacogenetics of irinotecan metabolism and transport: an update.Semantic proximity Read ↗

Irinotecan-Induced Toxicity: A Pharmacogenetic Study Beyond UGT1A1.Semantic proximity Read ↗

Pharmacogenetics of Irinotecan Disposition and Toxicity: A ReviewSemantic proximity Read ↗

Pharmacokinetic and Pharmacogenetic Markers of Irinotecan Toxicity.Semantic proximity Read ↗

Integration of DNA sequencing with population pharmacokinetics to improve the prediction of irinotecan exposure in cancer patients.Semantic proximity Read ↗

Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms.Semantic proximity Read ↗

The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer.Semantic proximity Read ↗

Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics.Semantic proximity Read ↗

Insights, challenges, and future directions in irinogenetics.Semantic proximity Read ↗

Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics.Semantic proximity Read ↗

Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer.Semantic proximity Read ↗

Pharmacogenetics of IrinotecanSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.